Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 versus intensive salvage therapy in adults 60 years or younger with acute myeloid leukemia in first relapse
2009-010951-28Phase 2Active
- Sponsor
- Celator Pharmaceuticals, Inc
- Start
- Aug 2009
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (2 arms), sponsored by Celator Pharmaceuticals, Inc. Primary endpoint: Proportion of patients surviving at 1 year. Started Aug 2009; status: active.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-010951-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010951-28.